Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

NIH 2INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1Gastrointestinal 1

Conditions

Leukemia, Myeloid, Acute 8Cholangiocarcinoma 3Recurrence 2Leukemia 2Glioma 2Neoplasms, Unknown Primary 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1IDH1-Mutated Malignancies 1Hematologic Neoplasms 1Chondrosarcoma 1

Interventions

Temozolomide 32Radiotherapy 11Bevacizumab 10Surgical Procedures, Operative 7IL13-PE38 7TIC10 compound 6Lomustine 6Carboplatin 6Radiation 5Chlorotoxin 5vorasidenib 4trametinib 4dabrafenib 4Valacyclovir 4OKN 007 4Flucytosine 4Dianhydrogalactitol 4Cyclophosphamide 4vocimagene amiretrorepvec 3abemaciclib 3Paclitaxel 3Nivolumab 3Irinotecan 3Granulocyte-Macrophage Colony-Stimulating Factor 3CLR1404 3trans-sodium crocetinate 2pembrolizumab 2olutasidenib 2marizomib 2lenvatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Glioma × ivosidenib × Clear all
NCT02073994 2026-02-17

Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation

Servier

Phase 1 Completed
174 enrolled
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Cholangiocarcinoma

NCT03343197 2026-02-17

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

Servier

Phase 1 Completed
49 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡